@article{oai:shiga-med.repo.nii.ac.jp:00000180,
 author = {平, 大樹 and 寺田, 智祐},
 issue = {1},
 journal = {滋賀医科大学雑誌},
 month = {Mar},
 note = {Departmental Bulletin Paper, To develop a personalized therapy with febuxostat, a novel anti-hyperuricemia drug, pharmacogenomic analyses were applied. 15 patients with hyperuricemia participated in this study. Blood samples were collected at every visit, and determined the concentrations of febuxostat in plasma and genotype of UGT1A*6, UGT1A1*28, CYP2C9*2, and CYP2C9*3. Dose-adjusted concentrations of febuxostat in plasma with homozygote of UGT1A1 were significantly higher than that of wild type. Multiple linear regression analysis which plasma urate value was used as a dependent variable, revealed the variants of UGT1A1s and pre-dosage of allopurinol were significant covariates. These results suggested that the variants of UGT1A1s have an influence on pharmacokinetics and therapeutic effects of febuxostat.},
 pages = {a09--a11},
 title = {母集団薬物動態解析法を用いた高尿酸血症治療薬の個別化投与設計（第11回基礎・臨床融合の学内共同研究発表会）},
 volume = {27},
 year = {2014}
}